This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (25)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Review  • Alert me on articles by topic

A Systematic Review

Sachin Kamal-Bahl, MS; Jalpa Doshi, MS; James Campbell, MD

Arch Pediatr Adolesc Med. 2002;156:1034-1041.

Objective  To systematically review all published economic analyses of the only 2 available agents for respiratory syncytial virus immunoprophylaxis in high-risk infants: respiratory syncytial virus immunoglobulin intravenous and palivizumab.

Data Sources  Economic evaluations of respiratory syncytial virus immunoprophylactic agents were identified from the MEDLINE and HealthSTAR databases using various combinations of the following search terms: respiratory syncytial virus immunoglobulin intravenous, palivizumab, cost, and cost-effectiveness. The search was limited to articles published in English between January 1, 1990, and August 31, 2001. Additional studies were obtained by searching bibliographies of all relevant identified articles.

Study Selection  Only studies that performed an economic analysis of either or both of these agents in an infant population were included. Letters to the editor and commentaries that included informal economic analyses were excluded. Twelve of the 21 identified studies met the selection criteria.

Data Extraction  Two of us (S.K.-B. and J.D.) independently reviewed the articles and extracted summary information using a standardized abstraction form, with differences resolved by consensus.

Data Synthesis  Estimates ranging from cost savings to considerable incremental costs per hospitalization avoided with use of either agent were observed across studies. Studies comparing the 2 agents reported mixed results about their relative cost-effectiveness in different infant subgroups. The divergent results may be explained by differences in the study methods and assumptions, but they also reflect the poor quality of some of the economic analyses.

Conclusion  In light of the issues identified in this review, providers, payers, and health policymakers need to critically appraise and judiciously interpret cost-effectiveness research on these agents.

From the Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy (Mr Kamal-Bahl and Ms Doshi), and the Center for Vaccine Development, University of Maryland School of Medicine (Dr Campbell), Baltimore.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Strategies for preventing respiratory syncytial virus
Forbes
Am J Health Syst Pharm 2008;65:S13-S19.
ABSTRACT | FULL TEXT  

Cost-effectiveness Analysis of Palivizumab in Premature Infants Without Chronic Lung Disease.
ElHassan et al.
Arch Pediatr Adolesc Med 2006;160:1070-1076.
ABSTRACT | FULL TEXT  

Diagnosis and Management of Bronchiolitis
Subcommittee on Diagnosis and Management of Bronch
Pediatrics 2006;118:1774-1793.
ABSTRACT | FULL TEXT  

Impact of Palivizumab on Admission to the ICU for Respiratory Syncytial Virus Bronchiolitis: A National Survey
Prais et al.
Chest 2005;128:2765-2771.
ABSTRACT | FULL TEXT  

Palivizumab for preterm infants. Is it worth it?
Embleton et al.
Arch. Dis. Child. Fetal Neonatal Ed. 2005;90:F286-f289.
ABSTRACT | FULL TEXT  

Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis
Heikkinen et al.
Arch. Dis. Child. Fetal Neonatal Ed. 2005;90:F64-F68.
ABSTRACT | FULL TEXT  

Direct Cost Analyses of Palivizumab Treatment in a Cohort of At-Risk Children: Evidence From the North Carolina Medicaid Program
Wegner et al.
Pediatrics 2004;114:1612-1619.
ABSTRACT | FULL TEXT  

Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease
Duppenthaler et al.
Arch. Dis. Child. 2004;89:961-965.
ABSTRACT | FULL TEXT  

Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections
Meissner et al.
Pediatrics 2003;112:1447-1452.
ABSTRACT | FULL TEXT  

Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin et al.
BMJ 2003;326:1167-1170.
ABSTRACT | FULL TEXT  

Economic Evaluations of Immunoprophylaxis in Infants at High Risk for Respiratory Syncytial Virus: Shedding Light or Creating Confusion?
Klassen
Arch Pediatr Adolesc Med 2002;156:1180-1181.
FULL TEXT